Oncology Practice Management Issues


July 2016, Vol 6, No 7

Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

ASCO Meeting Highlights, Hematologic Malignancies, Multiple Myeloma

Adding the recently approved daratumumab (Darzalex), a human, CD38-direct monoclonal antibody, to a standard regimen of bortezomib (Velcade) and dexamethasone improved progression-free survival (PFS) by >60% compared with the standard regimen in patients with relapsed or refractory multiple myeloma, according [ Read More ]